Analyst Ratings — September 24, 2026 — After Hours — Last 12 Hours (Pacific Time)

Executive Summary

Analyst activity over the past 12 hours skewed broadly bullish, with price target raises and bullish initiations outnumbering cuts and downgrades, though several notable PT reductions tempered the mood. Goldman Sachs dominated the session with a sweeping biotech coverage initiation blitz, while Meta Platforms attracted the most multi-firm attention — with nearly every major house reiterating or raising targets on AI momentum. Key themes: AI-driven upside across identity security (Okta), social media (Meta), and autonomous tech; clinical trial outcomes reshaping biotech sentiment; and McDonald's facing a rare wall of PT cuts from multiple firms simultaneously.

Analyst Action Breakdown

Net Sentiment: Mildly Bullish. Upgrades and PT raises outpace downgrades and cuts. The large volume of bullish initiations (Goldman Sachs biotech sweep, Piper Sandler alt-asset managers, Morgan Stanley IMAX) tilts the session positive, though concentrated PT cuts in McDonald's, Paychex, and Stitch Fix reflect pockets of real concern.

Top Analyst Calls

🟢 JPMorgan → CoreWeave (CRWV) — Upgrade

• Upgraded to Overweight from Neutral; set $125 price target on strong pricing dynamics in AI compute infrastructure.

🟢 JPMorgan → Meta Platforms (META) — PT Raise

• Raised PT to $920 from $820, maintains Overweight; cites continued AI progress as the core driver.

🟢 Tigress Financial → Meta Platforms (META) — PT Raise

• Raised PT to $995 from $945, maintains Buy; AI growth narrative remains the primary catalyst.

🟢 Citizens → Meta Platforms (META) — PT Raise

• Raised PT to $885 from $770, maintains bullish stance; AI growth potential underpins the upgrade.

🟢 RBC Capital → Okta (OKTA) — PT Raise

• Raised PT to $230 from $195, maintains Outperform; AI security demand driving accelerating growth.

🟢 Jefferies → Okta (OKTA) — PT Raise

• Raised PT to $240 from $200, maintains Buy; AI agent traction seen as a durable tailwind.

🟢 DA Davidson → Okta (OKTA) — PT Raise

• Raised PT to $235 from $190, maintains Buy; AI agent adoption cited as key growth driver.

🟢 JPMorgan → Royal Caribbean (RCL) — PT Raise

• Raised PT to $394 from $345, maintains Overweight; improved yield outlook supports the bullish case.

🔴 JPMorgan → Norwegian Cruise Line (NCLH) — PT Cut

• Cut PT to $13 from $17, maintains Overweight; yield outlook diverges sharply from Royal Caribbean.

🔴 Argus → Yum! Brands (YUM) — Downgrade

• Downgraded to Hold from Buy; growth concerns weigh on the quick-service restaurant giant.

🔴 Piper Sandler → Rollins (ROL) — Downgrade

• Downgraded to Neutral from Overweight, lowered PT; AI search disruption seen as a threat to the pest control company's customer acquisition model.

🔴 William Blair → Stitch Fix (SFIX) — Downgrade

• Downgraded to Market Perform from Outperform; customer growth concerns drive the rating cut.

🟢 Goldman Sachs → Multiple Biotech Initiations — Initiations

• Initiated or resumed coverage on 15+ biotech/pharma names including Insmed ($188 Buy), Jazz Pharmaceuticals (Buy), Tarsus Pharmaceuticals (Buy), Madrigal Pharmaceuticals (Buy), Revolution Medicines (Buy), and Krystal Biotech (Buy); also initiated Neutral ratings on Arrowhead, Kodiak Sciences, AbCellera, Alkermes, and others — a major sector coverage sweep.

🟢 Piper Sandler → Everpure (P) — PT Raise

• Raised PT to $162 from $133, maintains Overweight; strong growth outlook drives the significant target increase.

🔴 Goldman Sachs → Acadia Pharmaceuticals (ACAD) — Reiterate Sell

• Reiterated Sell with $17 PT following a clinical trial miss; stands in stark contrast to TD Cowen's Buy at $37.

🟢 Canaccord → GRAIL (GRAL) — Reiterate Buy

• Reiterated Buy with $80 PT following a favorable FDA advisory panel vote; regulatory momentum supports the thesis.

Firm Activity Summary

Goldman Sachs — 17 calls (12 bullish, 2 bearish, 3 neutral)

• ACAD (Sell reiterate), INTU (Sell reiterate), TARS (Buy initiate), MDGL (Buy initiate), RVMD (Buy initiate), INSM (Buy initiate), KRYS (Buy initiate), JAZZ (Buy initiate), IOVA (Buy initiate), KYMR (Early-Stage reiterate), CTNM (Early-Stage initiate), ALKS (Neutral resume), ABCL (Neutral resume), ARWR (Neutral initiate), KOD (Neutral initiate), ALM (Neutral initiate)

BMO Capital — 8 calls (2 bullish, 3 bearish, 3 neutral)

• ACAD (PT cut), ONON (PT raise), CALM (PT cut), PAYX (PT cut), PATH (PT cut), META (Market Perform reiterate), CIGI (Outperform reiterate), MCD (PT cut)

Cantor Fitzgerald — 7 calls (5 bullish, 0 bearish, 2 neutral)

• UNH (Overweight reiterate), ARCT (Overweight reiterate), AJG (Neutral reiterate), DY (Overweight reiterate), MESO (Overweight reiterate), ACRS (Overweight reiterate), ROIV (Overweight reiterate)

Citizens — 9 calls (6 bullish, 1 bearish, 2 neutral)

• META (PT raise), DKNG (PT cut), ABNB (Outperform reiterate), STWD (Outperform reiterate), BKNG (Market Perform reiterate), SPRB (Outperform reiterate), ALKT (Outperform reiterate), Blue Owl (upgrade/reiterate), MMED (n/a — separate firm)

Piper Sandler — 7 calls (5 bullish, 1 bearish, 1 neutral)

• ONON (Overweight reiterate), AJG (Overweight reiterate), GIS (Overweight reiterate), P/Everpure (PT raise), ARES (Overweight initiate), CG (Overweight initiate), CCNE (Overweight initiate), ROL (Downgrade to Neutral)

UBS — 7 calls (3 bullish, 2 bearish, 2 neutral)

• CTAS (PT raise), ADSK (Buy reiterate), MCD (Buy reiterate), EIX (PT cut), PAYX (PT cut), TSLA (Neutral reiterate), TRU (PT cut)

Mizuho — 7 calls (4 bullish, 2 bearish, 1 neutral)

• META (Outperform reiterate), SHOP (Outperform reiterate), SHW (Outperform reiterate), MTN (PT cut), MGM (PT cut), FOUR (PT cut), OKTA (PT raise, Neutral)

JPMorgan — 7 calls (4 bullish, 3 bearish)

• META (PT raise), RCL (PT raise), CRWV (Upgrade), MCD (PT cut), NCLH (PT cut), VIK (PT cut), REG (Overweight reiterate)

Stifel — 7 calls (4 bullish, 2 bearish, 1 neutral)

• OKTA (PT raise), SEI (PT raise), CTAS (PT raise), EPRX (Buy reiterate), GIS (Buy reiterate), MTN (PT cut), PAYX (PT cut), LNN (Hold reiterate)

H.C. Wainwright — 5 calls (all bullish)

• ORKA (Buy reiterate), ACIU (Buy reiterate), IMVT (Buy reiterate), IONS (Buy reiterate), PRTX (Buy reiterate)

Truist Securities — 5 calls (4 bullish, 0 bearish, 1 neutral)

• AFRM (Buy reiterate), SRRK (PT raise), SAIL (PT raise), CTAS (PT raise), MMED (Buy initiate)

BofA Securities — 5 calls (3 bullish, 1 bearish, 1 neutral)

• META (Buy reiterate), OKTA (PT raise, Neutral), CBRL (PT raise), LIFE (PT raise), GIS (PT cut), MGEE (Neutral initiate)

Oppenheimer — 4 calls (all bullish)

• LGND (Outperform reiterate), CTVA (Outperform reiterate), IONS (Outperform reiterate), HRMY (Outperform reiterate)

TD Cowen — 4 calls (3 bullish, 1 neutral)

• ACAD (Buy reiterate), INTC (Hold reiterate), MDWD (Buy reiterate), ALMR (Buy reiterate), OKTA (PT raise, Hold)

Bernstein SocGen — 4 calls (2 bullish, 1 bearish, 1 neutral)

• ONON (Outperform reiterate), PPG (Outperform reiterate), CTAS (Market Perform reiterate), GIS (PT cut), SFIX (PT cut)

StoneX — 4 calls (3 bullish, 1 bearish)

• ANGI (Buy reiterate), JBHT (Buy reiterate), DKNG (Buy reiterate), PPLI (PT cut)

Keefe Bruyette — 2 calls (1 bullish, 1 bearish)

• NMRK (Outperform reiterate), AJG (PT cut)

DA Davidson — 3 calls (2 bullish, 1 neutral)

• OKTA (PT raise), ALIT (PT cut, Buy), FSLY (Neutral reiterate)

BTIG — 3 calls (2 bullish, 1 bearish)

• CDNA (PT raise), GLNG (PT raise), ARCT (PT cut)

Guggenheim — 2 calls (both bullish)

• TVTX (PT raise), OKTA (PT raise)

Morgan Stanley — 2 calls (both bullish)

• META (Overweight reiterate), IMAX (Overweight initiate)

William Blair — 2 calls (1 bullish, 1 bearish)

• META (Outperform reiterate), SFIX (Downgrade)

RBC Capital — 4 calls (3 bullish, 1 bearish)

• OKTA (PT raise), NICE (PT raise), META (Outperform reiterate), MCD (PT cut)

Sector Trends

Technology & AI Identity Security was the standout bullish sector of the session. Okta (OKTA) received coordinated price target increases from at least six firms — Jefferies ($240), DA Davidson ($235), RBC ($230), Guggenheim ($227), BofA ($220), Stifel ($215), TD Cowen ($200), and Mizuho ($200) — all citing AI agent adoption and identity security demand as durable growth drivers. The near-unanimous bullish tone on Okta represents one of the clearest consensus shifts in this session. Meta Platforms similarly attracted broad-based PT raises across JPMorgan, Citizens, Tigress Financial, and reiterations from Morgan Stanley, BofA, RBC, Mizuho, and William Blair — all anchored to AI product momentum and the company's annual Connect event.

Biotech & Pharma saw the highest volume of activity, driven almost entirely by Goldman Sachs's sweeping initiation of coverage across 15+ names. The firm leaned bullish on commercial-stage biotechs (Insmed, Jazz, Tarsus, Madrigal, Revolution Medicines, Krystal Biotech, Iovanace) while adopting a more cautious Neutral stance on earlier-stage or higher-risk names (Arrowhead, Kodiak, AbCellera, Alkermes). Acadia Pharmaceuticals was the session's clearest biotech flashpoint — Goldman maintained its Sell at $17 while TD Cowen held its Buy at $37 following a clinical trial miss, illustrating sharp analyst disagreement on the same data set.

Consumer & Restaurants faced headwinds. McDonald's was hit with PT cuts from JPMorgan ($260), Evercore ISI ($300), BMO ($310), and RBC ($285), even as UBS, Jefferies, and KeyBanc maintained bullish ratings with higher targets — creating a notable divergence. Yum! Brands was downgraded by Argus. Stitch Fix faced a downgrade from William Blair and PT cuts from both Bernstein ($4) and Mizuho ($3), signaling deteriorating confidence in the personalized retail model. General Mills also saw mixed-to-negative action, with BofA and Bernstein cutting targets while Stifel and Piper Sandler held firm on Buy/Overweight ratings.

Market Implications

The session's clearest signal for investors is the AI identity security trade. The coordinated Okta PT raises from six or more firms — spanning bulls and neutrals alike — suggest analysts broadly agree that AI agent proliferation is a structural tailwind for identity management, even if they disagree on valuation. For investors already in the space, this consensus shift is meaningful; for those on the sidelines, the spread of targets ($200–$240) reflects genuine uncertainty about the pace of monetization.

Meta's wall of bullish analyst coverage following its Connect event reinforces the stock's position as the consensus AI-era large-cap pick among sell-side analysts. The divergence worth watching: BMO sits at Market Perform with a $580 target while JPMorgan is at $920 and Tigress at $995 — a $415 spread that reflects very different assumptions about AI monetization timelines. McDonald's tells the opposite story: a rare multi-firm PT cut wave signals that the company's reinvestment plan and strategy timeline are creating near-term earnings uncertainty, even among analysts who remain long-term bulls.

The Goldman Sachs biotech initiation sweep is worth monitoring for follow-through. When a major firm initiates on 15+ names simultaneously, it often signals institutional interest in rotating into the sector. The bullish tilt toward commercial-stage biotechs (Insmed, Jazz, Madrigal) over earlier-stage names suggests Goldman sees near-term catalysts in approved or late-stage assets rather than speculative pipelines. The CoreWeave upgrade from JPMorgan — to Overweight on strong AI compute pricing — adds another data point to the AI infrastructure buildout thesis that has dominated 2026 analyst sentiment.

Key Takeaways

• 🟢 CoreWeave (CRWV) — JPMorgan's upgrade to Overweight with a $125 PT is a high-conviction call on AI compute pricing power.
• 🟢 Okta (OKTA) — Six+ firms raised price targets simultaneously, making it the session's clearest consensus bullish shift on AI agent security demand.
• 🟢 Meta Platforms (META) — JPMorgan's $920 PT and Tigress's $995 PT lead a broad-based bullish wave following the Connect event; BMO's $580 Market Perform is the notable outlier.
• 🔴 McDonald's (MCD) — PT cuts from JPMorgan, Evercore ISI, BMO, and RBC signal near-term earnings pressure from the reinvestment plan, even as UBS and Jefferies hold bullish.
• 🔴 Stitch Fix (SFIX) — William Blair downgrade plus PT cuts from Bernstein ($4) and Mizuho ($3) reflect accelerating concern over customer attrition and guidance misses.
• 🔴 Yum! Brands (YUM) — Argus downgrade to Hold from Buy flags growth concerns at the QSR giant.
• 🔴 Rollins (ROL) — Piper Sandler's downgrade to Neutral cites AI search disruption as a new structural risk to customer acquisition — an unusual bear thesis for a pest control company.
• 🟢 Royal Caribbean (RCL) — JPMorgan's PT raise to $394 from $345 contrasts sharply with Norwegian Cruise Line's cut to $13 from $17, highlighting a widening quality gap within cruises.
• 🟢 Goldman Sachs Biotech Sweep — Bullish initiations on Insmed, Jazz, Madrigal, Revolution Medicines, Tarsus, Krystal Biotech, and Iovanace signal institutional interest in commercial-stage biotech.
• 🔴 Acadia Pharmaceuticals (ACAD) — Goldman's $17 Sell vs. TD Cowen's $37 Buy on the same trial data is the session's starkest analyst disagreement; the trial miss is clearly being interpreted very differently.
• 🟢 Everpure (P) — Piper Sandler's PT raise to $162 from $133 is one of the session's largest percentage target increases.
• 🔴 Paychex (PAYX) — PT cuts from UBS, Stifel, and BMO converge on revenue growth and execution concerns — a rare triple-cut from major firms.
• 🟢 GRAIL (GRAL) — Canaccord reiterates Buy at $80 following a favorable FDA advisory panel vote, a potentially significant regulatory milestone.
• 🟢 Piper Sandler Alt-Asset Initiations — New Overweight coverage on Ares Management and Carlyle Group signals bullish sentiment on alternative asset managers.
• 🔴 Norwegian Cruise Line (NCLH) — JPMorgan's PT cut to $13 from $17 (while maintaining Overweight) reflects a meaningfully weaker yield outlook versus cruise peers.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/